MICHAEL POWELL
CIK 1202793 · last filed 2026-06-10
MICHAEL POWELL is a corporate insider who has filed 58 SEC Form 4 insider transactions across 14 companies since 2007. The most recent filing, for BCAX, was dated Jun 10, 2026. Across all open-market trades the lifetime net is +$87.0M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $78.2M across reported positions. 57 SEC filings were submitted jointly with JAMES HEALY.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$78.23M
14
58
$87.04M
Filer Profile
MENLO PARK, CA 94025
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BCAX | Director | — | $22.81 | — | $0 | 2 | 2026-06-10 |
| Galera Therapeutics, Inc. (GRTX) Delisted | Director | — | $17.60 | — | $0 | 5 | 2023-06-16 |
| Checkmate Pharmaceuticals, Inc. (CMPI) Delisted | Director | — | $10.50 | — | $0 | 4 | 2022-05-31 |
| VERA | 10%+ Owner | 2,187,504 | $35.05 | $76.67M | $32.00M | 1 | 2021-05-18 |
| NXTC | 10%+ Owner | 222,655 | $7.00 | $1.56M | $27.56M | 1 | 2019-11-19 |
| SYNLOGIC, INC. (SYBX) Delisted | Director | 38,331 | $0.69 | $26.4K | $0 | 5 | 2019-06-07 |
| Iterum Therapeutics plc (ITRM) Delisted | 10%+ Owner | 81,768 | $0.03 | $2.5K | $26.00M | 1 | 2018-05-30 |
| SYNLOGIC, INC. (MIRN) Delisted | Director | 2,117,669 | — | — | $6.00M | 2 | 2016-09-06 |
| HUMANIGEN, INC (KBIO) Delisted | 10%+ Owner | 39,637 | — | — | $0 | 1 | 2013-02-07 |
| Trius Therapeutics Inc (TSRX) Delisted | Director | 9,302 | — | — | $3.98M | 7 | 2012-03-27 |
| Anthera Pharmaceuticals Inc (ANTH) Delisted | 10%+ Owner | 51,542 | — | — | -$1.09M | 1 | 2012-01-03 |
| Orexigen Therapeutics, Inc. (OREX) Delisted | Director | 3,236 | — | — | -$22.41M | 13 | 2011-06-06 |
| Molecular Templates, Inc. (THLD) Delisted | Director | — | — | — | $0 | 2 | 2008-05-14 |
| ANESIVA, INC. (ANSV) Delisted | Director | 3,703,769 | — | — | $15.00M | 5 | 2008-05-12 |
Recent Filings
58 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-10 | BCAX | Grant (A) | — | $0 | EDGAR |
| 2025-06-10 | BCAX | Grant (A) | — | $0 | EDGAR |
| 2023-06-16 | Galera Therapeutics, Inc. (GRTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-06-16 | Galera Therapeutics, Inc. (GRTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-05-31 | Checkmate Pharmaceuticals, Inc. (CMPI) Delisted | Disp (D) | — | $0 | EDGAR |
| 2021-08-10 | Checkmate Pharmaceuticals, Inc. (CMPI) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-06-21 | Checkmate Pharmaceuticals, Inc. (CMPI) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-06-17 | Galera Therapeutics, Inc. (GRTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-05-18 | VERA | Mixed | +11,659,104 | $32.00M | EDGAR |
| 2020-11-12 | Checkmate Pharmaceuticals, Inc. (CMPI) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.